Primary Sclerosing Cholangitis (PSC)

Welcome to the online home of the Chris M. Carlos and Catherine Nicole Jockisch Carlos Endowment for Primary Sclerosing Cholangitis (PSC). Thanks to support provided by this endowment, dedicated Mayo Clinic investigators and their teams are making strides to better understand and treat PSC patients, with the ultimate goal of developing a cure for this disease.

Follow the PSC page and stay up-to-date as we post news about advances in PSC research, clinical trials, and available resources.

PUBLIC PAGE
Mar 16, 2020

A Randomized, Placebo-controlled, Phase II Study of Obeticholic Acid for Primary Sclerosing Cholangitis

By Konstantinos N. Lazaridis, M.D. @klazaridis
In a recent paper, published in the Journal of Hepatology, Kowdley, et al., reported a randomized, placebo-controlled, dose-finding study of Obeticholic acid (OCA), which has been approved for the therapy of Primary Biliary Cholangitis (PBC). OCA is a potent farnesoid X receptor (FXR) and the study included 76 patients [...]
A Randomized, Placebo-controlled, Phase II Study of Obeticholic Acid for Primary Sclerosing Cholangitis
Mar 2, 2020

Effects of Tumor Necrosis Factor Antagonists in Patients on Primary Sclerosing

By Konstantinos N. Lazaridis, M.D. @klazaridis
In a recent study, published in the journal Clinical Gastroenterology and Hepatology, Hedin, et al., reported the effects of tumor necrosis factor (TNF) antagonists on liver function and efficacy in therapy of inflammatory bowel disease (IBD) among patients with Primary Sclerosing Cholangitis (PSC). This was retrospective study of 141 [...]
Effects of Tumor Necrosis Factor Antagonists in Patients on Primary Sclerosing
Feb 17, 2020

PSC Epidemiology and Outcomes in a Population-based Cohort

By Ethan McConkey, Moderator @ethanmcconkey
In a recent paper published in the Journal of Gastroenterology, Bakhshi et al., reported an update on the epidemiology and outcomes of Primary Sclerosing Cholangitis (PSC) in a population-based cohort. The authors found that the incidence (i.e., the occurrence of new cases per year) of PSC almost doubled from 2001 [...]
PSC Epidemiology and Outcomes in a Population-based Cohort
Feb 3, 2020

Genomic Profiling of Cholangiocarcinoma among PSC Patients

By Ethan McConkey, Moderator @ethanmcconkey
In a recent study, published in the journal Hepatology, Goeppert B. et al., reported genomic features of cholangiocarcinoma (i.e., bile duct cancer) in patients with primary sclerosing cholangitis (PSC). In this excellent international effort from 11 medical centers in eight countries, the authors carried out DNA sequencing of 42 [...]
Genomic Profiling of Cholangiocarcinoma among PSC Patients
Jan 20, 2020

Mayo Clinic launches Vancomycin clinical trial for Primary Sclerosing Cholangitis

By Konstantinos N. Lazaridis, M.D. @klazaridis
Mayo Clinic in Minnesota, Arizona and Florida is currently conducting a randomized placebo controlled clinical trial, examining the impact of oral vancomycin on markers of cholestasis among patients with PSC. The treatment period is approximately 18 months and requires about five clinic visits along with lab draws at home. [...]
Mayo Clinic launches Vancomycin clinical trial for Primary Sclerosing Cholangitis

Invite Others

Send an email to invite people you know to join the Primary Sclerosing Cholangitis (PSC) page.

Please login or register to send an invite.